Literature DB >> 7139119

Kinetics of intravenously administered heparin in normal humans.

C A de Swart, B Nijmeyer, J M Roelofs, J J Sixma.   

Abstract

Heparin of five commercially available brands was used to study the disappearance of heparin anticoagulant activity in normal humans. The drug was administered intravenously by bolus injection and by continuous infusion. Heparin anticoagulant activity was determined by two assays: a diluted activated partial thromboplastin time (APTT) and an assay based on inactivation of bovine factor Xa, using a clotting system. After a bolus injection, the data fitted neither single exponential nor zero-order clearance. In semilogarithmic plots, heparin anticoagulant activity disappeared according to a slightly convex curve almost always preceded by a rapid initial loss of heparin anticoagulant activity. This disappearance profile was observed with all heparin regardless of the brand or assay system. Heparin anticoagulant activity estimated by the APTT disappeared faster than heparin anticoagulant activity estimated by the anti-Xa activity in the first phase. As expected, higher anticoagulant levels with the anti-Xa assay than with the APTT were also found on continuous infusion in normals as well as in patients treated for deep vein thrombosis or pulmonary embolism. The experimental data suggested a model based on the combination of a saturable and a linear clearance mechanism. These experimental data provide reliable guidelines for adjustment of the dose of heparin in single patients.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7139119

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  29 in total

Review 1.  New thrombolytics, anticoagulants, and platelet antagonists: the future of clinical practice.

Authors:  R C Becker
Journal:  J Thromb Thrombolysis       Date:  1999-04       Impact factor: 2.300

2.  Adjunctive Pharmacologic Treatment: Focus on the Development of Low Molecular Weight Heparins.

Authors: 
Journal:  J Thromb Thrombolysis       Date:  1997       Impact factor: 2.300

Review 3.  Parenteral anticoagulants: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.

Authors:  David A Garcia; Trevor P Baglin; Jeffrey I Weitz; Meyer Michel Samama
Journal:  Chest       Date:  2012-02       Impact factor: 9.410

Review 4.  Pharmacology of Peripheral Arterial Disease in the Angio Suite: What Every Interventionalist Should Know.

Authors:  Micah M Watts
Journal:  Semin Intervent Radiol       Date:  2019-02-05       Impact factor: 1.513

Review 5.  Are We Able to Dose Protamine Accurately Yet? A Review of the Protamine Conundrum.

Authors:  Patrick Hecht; Martin Besser; Florian Falter
Journal:  J Extra Corpor Technol       Date:  2020-03

Review 6.  Use of the activated clotting time in anticoagulation monitoring of intravascular procedures.

Authors:  J Bowers; J J Ferguson
Journal:  Tex Heart Inst J       Date:  1993

Review 7.  Intravenous heparin dosing: patterns and variations in internists' practices.

Authors:  B M Reilly; R Raschke; S Srinivas; T Nieman
Journal:  J Gen Intern Med       Date:  1993-10       Impact factor: 5.128

Review 8.  Anticoagulation therapy in children.

Authors:  Milind D Ronghe; Christina Halsey; Nicholas J Goulden
Journal:  Paediatr Drugs       Date:  2003       Impact factor: 3.022

9.  Tight coupling of thrombin-induced acid hydrolase secretion and phosphatidate synthesis to receptor occupancy in human platelets.

Authors:  H Holmsen; C A Dangelmaier; S Rongved
Journal:  Biochem J       Date:  1984-08-15       Impact factor: 3.857

10.  Development of a population pharmacokinetic-pharmacodynamic model of a single bolus dose of unfractionated heparin in paediatric patients.

Authors:  Hesham Al-Sallami; Fiona Newall; Paul Monagle; Vera Ignjatovic; Noel Cranswick; Stephen Duffull
Journal:  Br J Clin Pharmacol       Date:  2016-05-02       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.